English

• Autor(a) principal: Pontes, Marcela Amaral
• Data de Publicação: 2023
• Outros Autores: Ribeiro, Alane Andrelino, Rover, Marina Raijche Mattozo, Leite, Silvana Nair
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Brazilian Journal of Pharmaceutical Sciences
• Texto Completo: https://www.revistas.usp.br/bjps/article/view/207333
• topic: Medicines Price; COVID-19; Access to Medicines; Coronavirus; Pandemic

The COVID-19 pandemic puts the healthcare systems at risk due to the still uncertain operational and financial impacts of it. The difficult economic conditions of the population also call for more attention from government officials to define strategies that guarantee access to health services and products. Maintaining the supply chain of pharmaceutical products is not only paramount to cover the immediate medical response but will be fundamental to reducing disruption of the healthcare system. Increasing drug prices during the pandemic is definitely not a strategy that contributes to access. In this sense, this commentary presents a criticism of a decision by the Brazilian government that may impact the availability in health services and the population’s access to medicines necessary for the maintenance of life.